Stryker SYK

NYSE SYK

$271.48 -4.95 (-1.79%)

As of: Sep 9, 2026 · 12:13 PM EDT

Key Stats

Market Cap104.48 Bn

P/E28.02

P/S4.04

Div. Yield0.01

Total Debt (Qtr)14.94 Bn

Revenue Growth (1y) (Qtr)9.42

Add ratio to table…

About

Stryker Corporation is a global leader in medical technologies, offering innovative products and services that help improve patient and healthcare outcomes. The company operates in the medical device industry, providing solutions across surgical equipment, navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment, intensive care disposable products, clinical communication platforms, artificial intelligence-assisted virtual care technology, products for traditional brain and open skull-based surgical procedures, minimally invasive treatments for stroke and venous thromboembolism, and implants for joint replacement and trauma surgeries. Stryker's products are sold in approximately 61 countries through company-owned subsidiaries, branches, and third-party dealers and distributors.

Stryker generates revenue primarily through the sale of its medical technology products and services to healthcare providers worldwide. The company's revenue stems from a diverse portfolio including surgical instruments, endoscopic systems, patient safety technologies, vascular intervention products, neurocranial devices, orthopaedic implants, and robotic-assisted surgery platforms. Most of its products are marketed directly to doctors, hospitals, and other healthcare facilities, with sales supported by a global commercial organization focused on building long-term customer relationships.

The company operates through the following segments: MedSurg and Neurotechnology and Orthopaedics.

MedSurg and Neurotechnology: This segment includes surgical equipment, patient and caregiver safety technologies, and navigation systems under the Instruments category; endoscopic and communications systems under Endoscopy; patient handling, emergency medical equipment, intensive care disposable products, clinical communication, and artificial intelligence-assisted virtual care platform technology under Medical; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke and venous thromboembolism under Vascular; and a comprehensive line of products for traditional brain and open skull-based surgical procedures, orthobiologic and biosurgery products including synthetic bone grafts and vertebral augmentation products under Neuro Cranial. Key product launches in 2025 include the Steri-Shield 8 operating room personal protection system, the Connected OR IP BRAVoE integration portfolio, the LIFEPAK 35 monitor/defibrillator, the Vocera Sync Badge for handsfree clinician communication, the Broadway System for stroke intervention, the Surpass Elite Flow Diverting Stent, and the OptaBlate BVN radiofrequency nerve ablation system. The segment also completed acquisitions of Guard Medical Inc. for Negative Pressure Wound Therapy and Advanced Medical Balloons (AMB) for indwelling fecal management systems.
Orthopaedics: This segment primarily includes implants used in total joint replacements such as hip, knee, shoulder, and ankle, as well as trauma and extremities surgeries. Stryker provides advanced implant designs and specialized instrumentation to support orthopaedic surgery and recovery. The company offers the Mako SmartRobotics platform, which enables robotic-arm assisted procedures for knee, hip, and shoulder replacements. In 2025, Stryker introduced the Mako 4 platform featuring the Q‑Guidance system, launched the Mako Total Hip with Advanced Primary and Revision application, and expanded the Mako Shoulder application integrating Tornier implants, Blueprint planning software, and Mako SmartRobotics. The Mako Shoulder application received initial clinical use in 2024 with a planned full commercial launch in the United States in the first quarter of 2026.

Stryker holds a leading position in several key medical technology markets, competing as one of five leading global competitors in Instruments, Endoscopy, Medical, and Vascular and Neuro Cranial categories. In Orthopaedics, the company is one of four leading global competitors for joint replacement, trauma and extremities products, and robotics. Its competitive advantages stem from a strong commitment to innovation, quality, and service, supported by significant investments in research and development and a robust intellectual property portfolio comprising approximately 5,600 United States patents and 9,000 patents in other countries as of December 31, 2025.

Stryker serves doctors, hospitals, and other healthcare facilities across approximately 61 countries. The company's customers include institutions and professionals involved in surgical procedures, emergency medical care, patient monitoring, and rehabilitation. While specific customer names are not disclosed in the filing, the company emphasizes its direct engagement with healthcare providers to understand clinical needs and improve patient outcomes through its products and services.

Investment Thesis

▲ Bull case

Stryker Corporation demonstrated resilience in core markets despite Q1 cyber disruption, with strong underlying fundamentals positioning it for robust full-year recovery as evidenced by record Q1 Mako installations and accelerating international growth driven by successful product launches like Pangaea in Europe and sustained momentum in Japan, where approvals of U.S.-developed innovations are fueling double-digit expansion and capturing share from peers in key orthopedic and trauma segments.
The reaffirmed full-year 2026 guidance for organic sales growth of 8% to 9.5% and adjusted EPS of $14.90 to $15.10 reflects management's confidence in recapturing deferred sales throughout the year, particularly as manufacturing normalizes and procedure rescheduling gains traction in H2, supported by healthy hospital capital expenditure trends and an elevated order book that indicates no deterioration in underlying demand for its differentiated portfolio including robotic-assisted surgery and trauma solutions.
Strategic M&A activity, exemplified by the recently closed Amplitude Vascular Systems acquisition for up to $835 million, provides a significant catalyst by expanding Stryker's peripheral vascular franchise into coronary indications through the POWER CAD I FIH study, leveraging its differentiated hydraulic IVL technology to address a large underserved market with potential to drive long-term growth beyond traditional orthopedics while integrating seamlessly with the existing Inari commercial infrastructure.
Operational excellence initiatives and disciplined cost management are expected to mitigate persistent input cost pressures from tariffs and inflation, allowing Stryker to absorb rising expenses without compromising margin targets, as reflected in its unchanged full-year operating margin guidance of approximately 50 basis points year-over-year improvement, driven by manufacturing efficiency gains and favorable geographic mix despite near-term headwinds.
The launch of innovative products like the TPX HD power tool and RPS handheld robotic system signals continued innovation penetration into adjacent markets such as ASCs and revision surgeries, where early surgeon feedback indicates strong adoption potential, creating new recurring revenue streams through service and consumables pull-through that complement core capital equipment sales and enhance customer stickiness across the Orthotech portfolio.

Stryker Corporation demonstrated resilience in core markets despite Q1 cyber disruption, with strong underlying fundamentals positioning it for robust full-year recovery as evidenced by record Q1 Mako installations and accelerating international growth driven by successful product launches like Pangaea in Europe and sustained momentum in Japan, where approvals of U.S.-developed innovations are fueling double-digit expansion and capturing share from peers in key orthopedic and trauma segments.
The reaffirmed full-year 2026 guidance for organic sales growth of 8% to 9.5% and adjusted EPS of $14.90 to $15.10 reflects management's confidence in recapturing deferred sales throughout the year, particularly as manufacturing normalizes and procedure rescheduling gains traction in H2, supported by healthy hospital capital expenditure trends and an elevated order book that indicates no deterioration in underlying demand for its differentiated portfolio including robotic-assisted surgery and trauma solutions.
Strategic M&A activity, exemplified by the recently closed Amplitude Vascular Systems acquisition for up to $835 million, provides a significant catalyst by expanding Stryker's peripheral vascular franchise into coronary indications through the POWER CAD I FIH study, leveraging its differentiated hydraulic IVL technology to address a large underserved market with potential to drive long-term growth beyond traditional orthopedics while integrating seamlessly with the existing Inari commercial infrastructure.
Operational excellence initiatives and disciplined cost management are expected to mitigate persistent input cost pressures from tariffs and inflation, allowing Stryker to absorb rising expenses without compromising margin targets, as reflected in its unchanged full-year operating margin guidance of approximately 50 basis points year-over-year improvement, driven by manufacturing efficiency gains and favorable geographic mix despite near-term headwinds.
The launch of innovative products like the TPX HD power tool and RPS handheld robotic system signals continued innovation penetration into adjacent markets such as ASCs and revision surgeries, where early surgeon feedback indicates strong adoption potential, creating new recurring revenue streams through service and consumables pull-through that complement core capital equipment sales and enhance customer stickiness across the Orthotech portfolio.

▼ Bear case

Stryker Corporation faces significant near-term execution risk as the cyber incident's impact on revenue recognition and production recovery remains unevenly distributed across its portfolio, with capital-intensive MedSurg businesses like LIFEPAK and endoscopy systems likely to experience prolonged recovery into H2 due to make-to-order complexities and rescheduling delays, potentially creating a lumpy sales cadence that could pressure quarterly performance despite full-year guidance being maintained.
Margin expansion expectations are under threat from persistent tariff headwinds and rising input costs tied to geopolitical instability, which management acknowledged as ongoing pressures that may not be fully absorbed through procurement efficiencies alone, especially given the 190 basis point YoY decline in Q1 adjusted gross margin to 63.6% driven by lost manufacturing absorption and tariff impacts, suggesting structural cost pressures could impede the path to the guided 50 basis point operating margin improvement.
While the Amplitude Vascular Systems acquisition expands Stryker's vascular footprint, its coronary PIVL technology remains in early-stage clinical testing with the POWER CAD I FIH study enrolling only up to 15 subjects, meaning commercialization is likely years away and near-term revenue contribution will be minimal, calling into question the timing and scale of synergies expected from integrating AVS with the Inari franchise and raising concerns about capital allocation efficiency if earlier-stage bets delay returns on recent M&A investments.
Competitive dynamics in the orthopedic market are intensifying as peer companies pursue spin-offs and sales force realignments, which could erode Stryker's market share gains in international regions like Latin America and Europe where it has historically relied on legacy relationships and incremental product launches rather than disruptive innovation, particularly if rivals accelerate adoption of next-generation robotic or digital surgery platforms that Stryker has not yet matched in pace or scope.
The company's reliance on procedural recovery to drive H2 sales assumes hospitals will reschedule deferred cases at historical rates, but ongoing strain on healthcare systems from staffing challenges and shifting site-of-care trends toward ASCs may reduce the elasticity of procedure volumes, limiting the upside from deferred demand and increasing the risk that some Q1 losses become permanent rather than merely delayed, especially for lower-acuity procedures that could migrate to competing settings.

Stryker Corporation faces significant near-term execution risk as the cyber incident's impact on revenue recognition and production recovery remains unevenly distributed across its portfolio, with capital-intensive MedSurg businesses like LIFEPAK and endoscopy systems likely to experience prolonged recovery into H2 due to make-to-order complexities and rescheduling delays, potentially creating a lumpy sales cadence that could pressure quarterly performance despite full-year guidance being maintained.
Margin expansion expectations are under threat from persistent tariff headwinds and rising input costs tied to geopolitical instability, which management acknowledged as ongoing pressures that may not be fully absorbed through procurement efficiencies alone, especially given the 190 basis point YoY decline in Q1 adjusted gross margin to 63.6% driven by lost manufacturing absorption and tariff impacts, suggesting structural cost pressures could impede the path to the guided 50 basis point operating margin improvement.
While the Amplitude Vascular Systems acquisition expands Stryker's vascular footprint, its coronary PIVL technology remains in early-stage clinical testing with the POWER CAD I FIH study enrolling only up to 15 subjects, meaning commercialization is likely years away and near-term revenue contribution will be minimal, calling into question the timing and scale of synergies expected from integrating AVS with the Inari franchise and raising concerns about capital allocation efficiency if earlier-stage bets delay returns on recent M&A investments.
Competitive dynamics in the orthopedic market are intensifying as peer companies pursue spin-offs and sales force realignments, which could erode Stryker's market share gains in international regions like Latin America and Europe where it has historically relied on legacy relationships and incremental product launches rather than disruptive innovation, particularly if rivals accelerate adoption of next-generation robotic or digital surgery platforms that Stryker has not yet matched in pace or scope.
The company's reliance on procedural recovery to drive H2 sales assumes hospitals will reschedule deferred cases at historical rates, but ongoing strain on healthcare systems from staffing challenges and shifting site-of-care trends toward ASCs may reduce the elasticity of procedure volumes, limiting the upside from deferred demand and increasing the risk that some Q1 losses become permanent rather than merely delayed, especially for lower-acuity procedures that could migrate to competing settings.

Stryker SYK

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Create an account

Sign In

Reset Password